Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xingnao Anshen Pian is a traditional Chinese medicine (TCM) developed and manufactured by Liaoning Jindan Pharmaceutical. It is an approved and marketed product in China, primarily indicated for the treatment of insomnia, dizziness, and neurasthenia. The formulation is designed based on TCM principles to nourish the heart, soothe the liver, and 'calm the spirit' (Anshen), while also 'waking the brain' (Xingnao) to improve mental clarity and cognitive function. It is typically used for patients presenting with symptoms of heart-spleen deficiency or liver-kidney disharmony, which manifest as sleep disturbances, anxiety, and memory loss. As a complex herbal formulation, it contains multiple active botanical ingredients that work synergistically to regulate the central nervous system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xingnao anshen pian.